AP2u2-CMV-Ace2-IgG1
(Plasmid
#226455)
-
PurposeMammalian expression of human Ace2 protein under CMV promoter fused with IgG1, tagged with 6His, and released extracellular environment after expression for protein purification
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 226455 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneAP2u2-mCherry
- Backbone size w/o insert (bp) 5216
- Total vector size (bp) 8180
-
Vector typeMammalian Expression
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert 1
-
Gene/Insert nameAngiotensin Converting Enzyme 2
-
Alt nameAce2
-
SpeciesH. sapiens (human)
-
Insert Size (bp)2220
-
GenBank ID59272
-
Tag
/ Fusion Protein
- 6xHis Tag (C terminal on insert)
Gene/Insert 2
-
Gene/Insert nameImmunoglobulin Heavy Constant Gamma 1
-
Alt nameIgG1
-
SpeciesH. sapiens (human)
-
Insert Size (bp)696
-
GenBank ID3500
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
AP2u2-CMV-Ace2-IgG1 was a gift from Urartu Seker (Addgene plasmid # 226455 ; http://n2t.net/addgene:226455 ; RRID:Addgene_226455) -
For your References section:
Screening Peptide Drug Candidates To Neutralize Whole Viral Agents: A Case Study with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Ozcelik CE, Araz CZ, Yilmaz O, Gulyuz S, Ozdamar P, Salmanli E, Ozkul A, Seker UOS. ACS Pharmacol Transl Sci. 2024 Mar 21;7(4):1032-1042. doi: 10.1021/acsptsci.3c00317. eCollection 2024 Apr 12. 10.1021/acsptsci.3c00317 PubMed 38633598